Exploring the Role of Antibody-Drug Conjugates in Cancer Care: A Foundational Program for Oncology Pharmacists

Release date: July 1, 2022,Expiration date: July 1, 2023.,Description:,New molecular entities continue to enter the treatment landscape for patients with hematologic malignancies and solid tumors. Though existing therapies have demonstrated efficacy, antibody-drug conjugates (ADCs) have been identified as having an improved therapeutic index and increased tumor selectivity. Pharmacists should be aware of the pharmacology and mechanisms of action of available and emerging ADCs in various malignancies. Indications for each of the ADCs currently FDA approved and others in the pipeline will be discussed throughout this program. A discussion of best practices for oncology pharmacists to manage the adverse effects of therapy as well as drug management strategies for the preparation, dispensing, and administration of ADCs to optimize care of patients with cancer will be presented. This program will also feature video animations highlighting the unique chemical structures and mechanisms of action of FDA-approved ADCs.,Educational Objectives,At the completion of this activity, participants will be able to:,• Differentiate antibody-drug conjugates in oncology by a unique mechanism of action and therapeutic targets.,• Identify the role of antibody-drug conjugates in various cancer indications based on supportive clinical data and guideline recommendations.,• Examine the role of the pharmacist in optimizing the use of antibody-drug conjugates in various cancer indications.